If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Address correspondence to John E. Morley, MB, BCh, Division of Geriatric Medicine, Saint Louis University School of Medicine, 1402 S. Grand Boulevard, M238, St Louis, MO 63104.
Dementia is defined as an acquired loss of memory that is substantial enough to interfere
with everyday functioning. Although many types of dementia exist, most patients with
dementia have Alzheimer's disease (AD), vascular dementia, or Lewy body dementia.
Age is the greatest risk factor for developing dementia; its incidence and prevalence
increase dramatically in persons older than 65 years. Specifically, AD affects approximately
25% to 30% of individuals older than 65 years and doubles in incidence for every 5
years thereafter. As a result, the prevalence of AD approaches 50% among persons older
than 85 years.
explored the age-related trajectories of memory loss in APOE carriers and noncarriers
and found that homozygous carriers have earlier onset of memory impairment than noncarriers
in the absence of mild cognitive impairment (MCI) or AD. Patients with AD have an
average life expectancy of 8 to 10 years after symptom onset and as the disease progresses
a loss in activities of daily living ensues. This entails caregiver burden and with
time it becomes so overwhelming that it is a major contributing factor to the decision
to institutionalize a patient with dementia. One approach to this highly prevalent
disease is its early detection for early treatment and prevention. For this reason
recent research has focused on detection of early dementia and the transitional stage
of cognitive impairment between normal aging and early dementia, so-called mild cognitive
impairment. Figure 1 gives a simple approach to the diagnosis of dementia and MCI.
This article intends to point out the ability of current screening tools to detect
MCI and dementia, and to summarize 3 aspects of these conditions: prognosis, diagnosis,
and treatment, in the community as well as nursing home settings.
Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology.
Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder—A pilot study.
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
The article, “Early Detection of Cognitive Impairment: Do Screening Tests Help?” by Cruz-Oliver and Morley that appeared in the January 2010 issue of the Journal of the American Medical Directors Association (Vol. 11, No. 1, pp. 1–6), was published with errors to Figure 1 and Table 2. The corrected version of each is shown below.
